Chris Rusconi is a biotechnology entrepreneur, inventor, and innovator with a focus on the oligonucleotide space and extensive drug discovery and development experience. He serves as DiNAQOR’s Chief Development Officer.
An expert in leveraging platform science to create product pipelines, Dr. Rusconi has held leadership roles with both publicly traded and privately held companies. He spearheaded the science of Regado Biosciences from its founding through multiple rounds of private equity raises, IPO and secondary public offerings to a market capitalization of more than $400 million. He is an inventor on more than 70 issued and pending patents and author of more than 40 peer-reviewed publications.
Dr. Rusconi joins DiNAQOR from the PKD Foundation, a not-for-profit organization dedicated to finding treatments and a cure for polycystic kidney disease (PKD). He also served as the Chief Scientific Officer at Vitrisa Therapeutics, the founding CEO of Ribometrix, and was a co-founder and Chief Scientific Officer at Regado Biosciences. Prior to Regado he served as director of research for the Program in Combinatorial Therapeutics and as an assistant research professor of surgery at Duke University Medical Center.
Dr. Rusconi currently serves as co-director of the PKD Outcomes Consortium, a regulatory science collaboration focused on advancing treatments for PKD. He earned a PhD in Molecular and Cellular Biology from the University of Colorado, Boulder as an NSF Graduate Fellow and was a Jane Coffin Childs Postdoctoral Fellow at Duke University.